EUSA Pharma has gained backing from NICE for its first-line treatment for advanced renal cell carcimona (RCC), Fotivda. The recommendation from the UK’s regulatory body was decided on the result of the phase III trial TiVO-1, which evaluated the efficacy and tolerability of Fotivda compared to Bayer’s Nexavar.
Regulatory Affairs AssociateRegulatory ProfessionalsBuckinghamshire, Berkshire, >UK
- FULL TIME
Director of Regulatory CMCRegulatory ProfessionalsUK, Cambridgeshire
- FULL TIME
Regulatory Packaging and Artwork Project ManagerRegulatory ProfessionalsUK, Surrey
- FULL TIME
Senior / Principle Regulatory ConsultantRegulatory ProfessionalsUK, Hertfordshire
- FULL TIME
Regulatory Professionals is one of the fastest growing global integrated regulatory outsourcing providers with a network of 20,000 pharmaceutical professionals globally. Working exclusively within the regulatory functions of Pharmaceutical, Biotechnology, Medical Device, Consumer health / OTC and Diagnostics industries.
Our integrated regulatory affairs recruitment team is there to support partner organisations of all sizes. Ranging for one regulatory consultant, to deliver a specialist project, to outsourcing functional regulatory teams of over 100+, Regulatory Professionals are able to offer global support partnered with expert local knowledge. Our capabilities also offer contract and permanent regulatory staffing services to allow a 360 degree service range for all aspects of regulatory delivery.
Our regulatory recruitment teams approach is tailored to meet the needs of our partners requirements allowing you to shift internal R&D focus to more strategic activities to improve lifecycle performance.
The benefits of Regulatory Professionals integrated teams are measured not just in the savings that could result in multi-mullion dollar cost reductions, but equally in understanding that delays in any part of the regulatory cycle affect the ability to give patients access to transformational products.
Our integrated teams support your product portfolio by giving you flexibility of resource at the peaks and troughs of the product life cycle, while ensuring you maintain control of strategic regulatory departments. This is supported by consistent, measurable and tracked metrics to maximise accountability.
To find out more about each of the regulatory areas we specialise in, take a look at the following regulatory recruitment services:
Our experienced specialist recruitment consultants are available to speak to you confidentially about our outsourcing regulatory affairs services. To find out more information or to discuss any of our regulatory vacancies, please call our specialist regulatory affairs recruitment team.
Contact us today to find out how we can progress your career to the next level
NICE have issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF) in England and Wales, but only for those with moderate to severe forms of the disease. The cost regulators are sticking with its position that Esbriet should only be funded by the NHS if the person
NICE issues final green light and thus securing routine NHS funding for Roche’s Perjeta in patients with a certain type of breast cancer. The guidelines follow a confidential commercial agreement for Perjeta between NHS England and the Roche late last year, allowing for its move from the Cancer Drugs Fund to the NHS’ routine commissioning